Not much has been easy for Agoura Hills-based Acelyrin since going public on May 4 with shares plummeting 88% since its IPO and so far, even a potential merger the company had lined up has become muddled. Acelyrin, a pre-revenue biotechnology company that is backed by Westlake Village BioPartners, announced in early February that it…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
